Peter J Lenting Selected Research

von Willebrand Factor

8/2022	Cerebral Microbleeds During Transcatheter Aortic Valve Replacement: A Prospective Magnetic Resonance Imaging Cohort.
5/2022	Towards novel treatment options in von Willebrand disease.
1/2022	The VWF/LRP4/αVβ3-axis represents a novel pathway regulating proliferation of human vascular smooth muscle cells.
1/2022	Microlyse: a thrombolytic agent that targets VWF for clearance of microvascular thrombosis.
1/2021	Development of a dual hybrid AAV vector for endothelial-targeted expression of von Willebrand factor.
1/2021	The von Willebrand Factor A1 domain mediates thromboinflammation, aggravating ischemic stroke outcome in mice.
1/2021	von Willebrand disease: what does the future hold?
11/2020	Coagulation biomarkers are independent predictors of increased oxygen requirements in COVID-19.
10/2020	Camelid-derived single-chain antibodies in hemostasis: Mechanistic, diagnostic, and therapeutic applications.
12/2019	Relevance of platelet desialylation and thrombocytopenia in type 2B von Willebrand disease: preclinical and clinical evidence.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Peter J Lenting Research Topics

Disease

22	Hemorrhage 08/2022 - 01/2004
19	Thrombosis (Thrombus) 01/2022 - 09/2003
13	Hemophilia A (Haemophilia) 01/2022 - 04/2005
11	von Willebrand Diseases (von Willebrand's Disease) 05/2022 - 11/2005
7	Thrombocytopenia (Thrombopenia) 01/2022 - 08/2007
7	Type 2 von Willebrand Disease 12/2019 - 11/2005
5	Thrombotic Thrombocytopenic Purpura 01/2022 - 11/2005
4	Inflammation (Inflammations) 01/2022 - 02/2016
3	Aortic Valve Stenosis (Aortic Stenosis) 07/2016 - 03/2015
2	Neoplasms (Cancer) 01/2022 - 01/2013
2	COVID-19 12/2020 - 11/2020
2	Vascular System Injuries 01/2019 - 10/2016
2	Body Weight (Weight, Body) 11/2017 - 08/2009
2	Aortic Valve Insufficiency (Aortic Regurgitation) 07/2016 - 03/2015
2	Infections 02/2010 - 04/2007
1	Virus Diseases (Viral Diseases) 01/2022
1	Hyperplasia 01/2022
1	Reperfusion Injury 01/2021
1	Thromboinflammation 01/2021
1	Ischemic Stroke 01/2021
1	Venous Thrombosis (Deep-Vein Thrombosis) 01/2021
1	Paraproteinemias (Monoclonal Gammopathy) 01/2021
1	Brain Ischemia (Cerebral Ischemia) 01/2021
1	Hypertension (High Blood Pressure) 11/2020
1	Metabolic Syndrome (Dysmetabolic Syndrome X) 11/2020
1	Heart Valve Diseases (Valvular Heart Disease) 12/2019
1	Hemophilia B (Haemophilia B) 12/2019
1	Arterial Occlusive Diseases (Arterial Occlusive Disease) 08/2017
1	Thrombotic Stroke 08/2017
1	Carotid Artery Thrombosis 08/2017
1	Intracranial Hemorrhages (Intracranial Hemorrhage) 08/2017

Drug/Important Bio-Agent (IBA)

39	von Willebrand FactorIBA 08/2022 - 03/2004
9	Factor VIII (Coagulation Factor VIII)IBA 11/2020 - 05/2003
8	AntibodiesIBA 01/2021 - 01/2004
8	Proteins (Proteins, Gene)FDA Link 01/2020 - 08/2004
5	Glycoproteins (Glycoprotein)IBA 01/2022 - 03/2004
5	AntigensIBA 01/2021 - 03/2007
5	Hemostatics (Antihemorrhagics)IBA 10/2016 - 04/2012
4	Deamino Arginine Vasopressin (Desmopressin)FDA LinkGeneric 05/2022 - 03/2013
4	emicizumabIBA 01/2021 - 01/2019
4	Thrombin FDA Link 01/2021 - 08/2017
4	CollagenIBA 03/2013 - 03/2008
3	thiamine triphosphorate (TTP)IBA 01/2022 - 11/2005
3	Fibrinolytic Agents (Antithrombotic Agents)IBA 01/2022 - 08/2017
3	Factor X (Stuart Factor)IBA 01/2020 - 02/2016
3	Blood Coagulation Factors (Coagulation Factor)IBA 01/2020 - 04/2005
3	ferric chlorideIBA 08/2017 - 09/2008
3	Platelet Glycoprotein GPIb-IX Complex (Glycoprotein Ib)IBA 01/2015 - 01/2009
2	Adenosine Diphosphate (ADP)IBA 08/2022 - 07/2016
2	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 01/2022 - 03/2011
2	caplacizumabIBA 01/2022 - 10/2020
2	Fibrinogen (Factor I)FDA Link 01/2022 - 11/2020
2	lipoprotein-associated coagulation inhibitor (TFPI)IBA 12/2020 - 01/2020
2	Oxygen (Dioxygen)IBA 12/2020 - 11/2020
2	AnticoagulantsIBA 01/2020 - 11/2019
2	Single-Domain AntibodiesIBA 01/2020 - 01/2017
2	SerpinsIBA 01/2020 - 11/2019
2	AntithrombinsIBA 01/2020 - 01/2020
2	IntegrinsIBA 01/2018 - 12/2013
2	LigandsIBA 01/2015 - 08/2008
2	Complementary DNA (cDNA)IBA 08/2008 - 03/2008
2	LDL Receptors (LDL Receptor)IBA 08/2004 - 05/2003
1	Heparin (Liquaemin)FDA LinkGeneric 08/2022
1	Protamines (Protamine Sulfate)FDA Link 08/2022
1	Antifibrinolytic Agents (Antifibrinolytics)IBA 05/2022
1	OsteoprotegerinIBA 01/2022
1	Member 2 Protein Solute Carrier Family 44IBA 01/2021
1	SuspensionsIBA 01/2021
1	EpitopesIBA 01/2021
1	fitusiranIBA 12/2020
1	C-Reactive ProteinIBA 11/2020
1	Biomarkers (Surrogate Marker)IBA 11/2020
1	Anti-Idiotypic AntibodiesIBA 01/2020
1	prothrombin complex concentrates (PPSB)IBA 01/2020
1	RNA (Ribonucleic Acid)IBA 01/2020
1	Protein CIBA 01/2020
1	Messenger RNA (mRNA)IBA 01/2020
1	Factor IXa (Coagulation Factor IXa)IBA 01/2020
1	Factor VIIa (Activated Factor VII)IBA 01/2020
1	cancer procoagulantIBA 12/2019
1	Peptide Hydrolases (Proteases)FDA Link 11/2019
1	Thromboplastin (Tissue Factor)IBA 11/2019
1	Factor IX (Coagulation Factor IX)FDA LinkGeneric 11/2019
1	Neutralizing AntibodiesIBA 02/2019
1	7,7'- dimethoxy- (4,4'- bi- 1,3- benzodioxole)- 5,5'- dicarboxylic acid dimethyl ester (BDD)IBA 01/2018
1	Protein Kinase CIBA 01/2018
1	Monomeric GTP-Binding ProteinsIBA 01/2018
1	Collagenases (Collagenase)FDA Link 08/2017
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 11/2016
1	SelectinsIBA 11/2016
1	Lim KinasesIBA 10/2016
1	Actin Depolymerizing Factors (Cofilins)IBA 10/2016

Therapy/Procedure

7	Therapeutics 05/2022 - 01/2013
6	Surgical Instruments (Clip) 01/2022 - 01/2017
2	Lasers (Laser) 12/2019 - 08/2017
2	Transcatheter Aortic Valve Replacement 07/2016 - 03/2015
2	Heart-Assist Devices 01/2016 - 03/2015
1	Ligation 01/2022
1	Intravenous Infusions 02/2019
1	Hepatectomy 11/2017